Calidi Biotherapeutics announces annual shareholder meeting via webcast

Calidi Biotherapeutics, Inc.

Calidi Biotherapeutics, Inc.

CLDI

0.00

  • Calidi Biotherapeutics scheduled virtual annual shareholder meeting for June 12, 2026.
  • Shareholders set to vote on election of Class III director nominee Scott Leftwich to serve until 2029 annual meeting.
  • Ballot includes auditor ratification for CBIZ CPAs P.C. for fiscal 2026.
  • Investors to consider reverse stock split ratio range of 1-for-2 to 1-for-16.
  • Meeting agenda also includes amendment to 2023 Equity Incentive Plan to raise share authorization to 1,950,000, plus potential adjournment to solicit additional votes.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Calidi Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-017935), on April 17, 2026, and is solely responsible for the information contained therein.